Clues to quality of journals
Open Access Policy of Helmholtz Association 2016
CC Licencences
Publication Metrics
Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Statistics (last 5 years)
OA Publications
Submit Publication
Import publication from...
Report missing publication
Contact persons
Help
Text
Endnote (RIS)
BibTeX
Publ. Version/Full Text
DOI
PMC
 |
Open Access Hybrid |
|
as soon as is submitted to ZB.
Changes in cerebrospinal fluid concentrations of selenium species induced by tofersen administration in subjects with amyotrophic lateral sclerosis Carrying SOD1 gene mutations.
Biol. Trace Elem. Res., DOI: 10.1007/s12011-024-04311-4 (2024)
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease affecting the brain and spinal cord motor neurons. On 25 April 2023, the drug tofersen, an antisense oligonucleotide, received the US Food and Drug Administration approval for treating ALS in adults carrying mutations of the SOD1 gene. We aimed at assessing whether cerebrospinal fluid concentrations of selenium, an element of both toxicological and nutritional interest possibly involved in disease etiology and progression, are modified by tofersen administration. We determined concentrations of selenium species by anion exchange chromatography hyphenated to inductively coupled plasma-dynamic reaction cell-mass spectrometry and overall selenium by using inductively coupled plasma sector-field mass spectrometry, at baseline and 6 months after active tofersen treatment in ten Italian ALS patients carrying the SOD1 gene mutation. Concentrations of total selenium and many selenium species substantially increased after the intervention, particularly of inorganic (tetravalent and hexavalent) selenium and of the organic species selenomethionine and a compound co-eluting with the selenocystine standard. Overall, these findings suggest that tofersen treatment markedly alters selenium status and probably the redox status within the central nervous system, possibly due to a direct effect on neurons and/or the blood-brain barrier. Further studies are required to investigate the biological and clinical relevance of these findings and how they might relate to the pharmacological effects of the drug and to disease progression.
Impact Factor
Scopus SNIP
Altmetric
3.400
0.000
Annotations
Special Publikation
Hide on homepage
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Amyotrophic Lateral Sclerosis ; Sod1 ; Selenium ; Selenium Compounds ; Tofersen; Antisense Oligonucleotide Tofersen; Human Serum; Selenoproteins; Neurotoxicity; Speciation; Toxicity; Therapy; Humans; Health; Trial
Language
english
Publication Year
2024
HGF-reported in Year
2024
ISSN (print) / ISBN
0163-4984
e-ISSN
1559-0720
Publisher
Springer
Publishing Place
Campus, 4 Crinan St, London, N1 9xw, England
Reviewing status
Peer reviewed
Institute(s)
Research Unit BioGeoChemistry and Analytics (BGC)
POF-Topic(s)
30202 - Environmental Health
Research field(s)
Environmental Sciences
PSP Element(s)
G-504800-002
Grants
Ministero dell'Istruzione, dell'Universit e della Ricerca
WOS ID
001270435700001
Scopus ID
85198848014
PubMed ID
39017978
Erfassungsdatum
2024-07-18